MR3V3Hzj4H | 2095304-61-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: MR3V3Hzj4H
• 英文别名: (2S)-2-hydroxy-2-methyl-N-[(3R)-piperidin-3-yl]-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanamide
• CAS: 2095304-61-1
• 化学式: C₁₉H₂₈N₂O₄
• 分子量: 348.4
• InChiKey: LEKUGUATSGETDB-KUHUBIRLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  95.5
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• Compounds for treating mitochondrial disease
  申请人：Khondrion IP B.V.

  公开号：US10815211B2

  公开（公告）日：2020-10-27

  The invention relates to novel compounds that are useful for modulating cellular ROS. The compounds are amide-derivatives of 2-hydroxy-2-methyl-4-(3,5,6-trimethyl-1,4-benzoquinon-2-yl)-butanoic acid. The compounds of the invention are formulated into pharmaceutical or cosmetic compositions. The invention further relates to methods wherein the compounds of the invention are used for treating or preventing diseases associated with increased ROS levels mitochondrial disorders and/or conditions associated with mitochondrial dysfunction, including adverse drug effects. The invention also relates to cosmetic methods for treating or delaying further aging of the skin and veterinary applications.

  本发明涉及可用于调节细胞 ROS 的新型化合物。这些化合物是 2-羟基-2-甲基-4-(3,5,6-三甲基-1,4-苯醌-2-基)-丁酸的酰胺衍生物。本发明的化合物可配制成药物或化妆品组合物。本发明进一步涉及本发明化合物用于治疗或预防与 ROS 水平升高相关的疾病线粒体紊乱和/或与线粒体功能障碍相关的病症（包括药物不良反应）的方法。本发明还涉及治疗或延缓皮肤进一步衰老的美容方法和兽医应用。
• Novel compounds for treating mitochondrial disease
  申请人：Khondrion IP B.V.

  公开号：US20210024484A1

  公开（公告）日：2021-01-28

  The invention relates to novel compounds that are useful for modulating cellular ROS. The compounds are amide-derivatives of 2-hydroxy-2-methyl-4-(3,5,6-trimethyl-1,4-benzoquinon-2-yl)-butanoic acid. The compounds of the invention are formulated into pharmaceutical or cosmetic compositions. The invention further relates to methods wherein the compounds of the invention are used for treating or preventing diseases associated with increased ROS levels mitochondrial disorders and/or conditions associated with mitochondrial dysfunction, including adverse drug effects. The invention also relates to cosmetic methods for treating or delaying further aging of the skin and veterinary applications.